Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school

Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school

Abstract Background Metastatic colorectal cancer imposes a substantial burden on patients and society. Over the last years, progresses in the treatment have been made especially due to the introduction of monoclonal antibodies, such as bevacizumab which, on the other hand, has considerably increased...

Full description

Bibliographic Details
Main Authors: Andrea Queiróz Ungari, Leonardo Régis Leira Pereira, Altacílio Aparecido Nunes, Fernanda Maris Peria
Format: Article
Language:English
Published: BMC 2017-10-01
Series:BMC Cancer
Subjects:
Colorectal Neoplasms
Cost-effectiveness evaluation
Bevacizumab
Unified health system
Brazil
Online Access:http://link.springer.com/article/10.1186/s12885-017-3679-5

Similar Items

Similar Items